WO2003059408A2 - Surgical patches with a biological active agent - Google Patents

Surgical patches with a biological active agent Download PDF

Info

Publication number
WO2003059408A2
WO2003059408A2 PCT/CA2002/002017 CA0202017W WO03059408A2 WO 2003059408 A2 WO2003059408 A2 WO 2003059408A2 CA 0202017 W CA0202017 W CA 0202017W WO 03059408 A2 WO03059408 A2 WO 03059408A2
Authority
WO
WIPO (PCT)
Prior art keywords
patch
agent
surgical
derivatives
chem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2002/002017
Other languages
English (en)
French (fr)
Other versions
WO2003059408A3 (en
Inventor
Pierre E. Signore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiotech Pharmaceuticals Inc
Angiotech International AG
Original Assignee
Angiotech Pharmaceuticals Inc
Angiotech International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiotech Pharmaceuticals Inc, Angiotech International AG filed Critical Angiotech Pharmaceuticals Inc
Priority to EP02787305A priority Critical patent/EP1465680A2/en
Priority to JP2003559568A priority patent/JP2005514171A/ja
Priority to CA002470499A priority patent/CA2470499A1/en
Priority to NZ533499A priority patent/NZ533499A/en
Priority to BR0215397-1A priority patent/BR0215397A/pt
Priority to AU2002351632A priority patent/AU2002351632A1/en
Priority to MXPA04006319A priority patent/MXPA04006319A/es
Publication of WO2003059408A2 publication Critical patent/WO2003059408A2/en
Publication of WO2003059408A3 publication Critical patent/WO2003059408A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances

Definitions

  • This invention relates to surgical patches coated with biologically active agents to prevent adverse tissue reaction to the patch.
  • Patch angioplasty is two techniques of arteriotomy closure used by surgeons after vascular procedures.
  • the lips of the arterial wound are directly sutured to each other whereas an extra piece of material is sutured between the two lips during patch angioplasty.
  • Patch angioplasty is preferred after procedures with a high rate of postoperative narrowing of the repaired vessel (endarterectomy of small carotid arteries for example).
  • the added piece of material maintains the original diameter of the blood vessel and induces favorable local hemodynamics that otherwise may lead to recurrent stenosis.
  • Patch angioplasty can be performed with autologous tissue (typically the patient's saphenous vein) or synthetic material (expanded polytetrafluoroethylene or Dacron).
  • Vein patches have drawbacks such as aneurismal degeneration and rupture. They require an additional incision to harvest the vein with associated morbidity.
  • the patient veins may not be suitable for patching.
  • the vein used for the patch will not be available for coronary artery bypass grafting should the patient require arterial reconstruction at a later time. For these reasons, the use of synthetic patches has become increasingly popular.
  • inflammatory cells such as macrophages, lymphocytes and neutrophils adhere to the prosthetic lumen and also migrate into the peri-prosthetic space. These cells release cytokines that promote smooth muscle cell migration from the adjacent vessel on the luminal surface of the patch. The cells further proliferate on the patch and secrete extracellular matrix. Depending on the porosity of the patch material, cells may also migrate through the pores of the patch from the surrounding tissue into the lumen. In both cases, hyperplasia causes plaque formation on the luminal surface of the patch and the adjacent vessels within a few weeks. This reduces luminal area in the treated blood vessel thus impeding blood flow to the distal tissues.
  • the present invention involves methods of making and using surgical patches which release agents that prevent inflammatory reactions, thrombus formations and/or intimal hyperplasia.
  • agents include cell-cycle inhibitors such as taxanes, camptothecins, doxorubicin, immunosuppressive drugs (rapamycin, cyclosporines), bromocryptine, tubercidine, beta-lapachone, glucocorticoids, nonsteroidal anti-inflammatory drugs, cell cycle inhibitors, calcium channel blockers, calcium chelating agents, inhibitors of matrix metalloproteinases, methotrexate, thrombolytic agents, anti-platelet agents and anticoagulation agents.
  • the presence of these agents, alone or in combination, on the patch will effectively prevent or inhibit local inflammatory reaction, prevent thrombus material from building up on the patch and stop cells from proliferating onto the patch.
  • surgical patches e.g., vascular patches
  • an anti-inflammatory agent e.g., an anti- platelet agent, an anticoagulant agent, fibrinolytic agents, a cell-cycle inhibitor agent, and/or an anti-proliferative agent.
  • the vascular patch is a synthetic patch (e.g., made of Dacron).
  • the anti- inflammatory agent is aspirin, ibuprofen, or a glucocorticoid drug
  • the anti-coagulant agent is heparin or hirudin
  • the fibrinolytic agent is tissue plasminogen activator, streptokinase, or urokinase.
  • the cell-cycle inhibitor agent is a taxane (e.g., paclitaxel or docetaxel), a vinca alkaloid (e.g., vinblastine or vincristine), a podophyllotoxin (e.g., etoposide), an anthracycline (e.g., doxorubicin or mitoxantrone), or a platinum compound (e.g., cisplatin or carboplatin).
  • a taxane e.g., paclitaxel or docetaxel
  • a vinca alkaloid e.g., vinblastine or vincristine
  • a podophyllotoxin e.g., etoposide
  • an anthracycline e.g., doxorubicin or mitoxantrone
  • platinum compound e.g., cisplatin or carboplatin
  • Also provided are methods for making surgical patches e.g., vascular patches which release an anti-inflammatory agent, an anti-platelet agent, an anticoagulant, an anti-fibrinolytic agent, a cell-cycle inhibitor, and/or an anti- proliferative agent, comprising the step of coating at least a part (all or a portion such as the ends, or one side) of the patch (e.g., by spraying or dipping) with one of the factors or agents mentioned above.
  • Alternative methods for generating patches e.g., interweaving a patch with a coated thread, or absorbing a desired agent onto the patch are described in more detail below.
  • the factor or agent may be mixed or formulated with another compound or carrier (e.g., polymeric or non- polymeric).
  • another compound or carrier e.g., polymeric or non- polymeric.
  • only one side of the patch is coated leaving the other side and most of the thickness of the patch untreated.
  • only parts (the edge for example) of the patch are coated.
  • methods are provided for closing an opening in the biological tissue (e.g., the vasculature), comprising applying to the opening in a surgical patch as described herein.
  • the compound or composition may be applied by itself or in a carrier, which may be either polymeric, or non-polymeric.
  • the surgical patch is a vascular patch, which is sutured in place.
  • Figure 1 is a schematic illustration showing sites of action within a biological pathway where Cell Cycle Inhibitors may act to inhibit the cell cycle.
  • Cell Cycle Inhibitor refers to any protein, peptide, chemical or other molecule which delays or impairs a dividing cell's ability to progress through the cell cycle and replicate.
  • Cell cycle inhibitors which prolong or arrest mitosis (M-phase) or DNA synthesis (S-phase), are particularly effective for the purposes of this invention as they increase the dividing cell's sensitivity to the effects of radiation.
  • M-phase mitosis
  • S-phase DNA synthesis
  • a wide variety of methods may be utilized to determine the ability of a compound to inhibit the cell cycle including univariate analysis of cellular DNA content and multiparameter analysis (see the Examples).
  • Patches are small pieces of material used to mend a tear or a break to cover a hole or to strengthen a weak place.
  • surgical patches are pieces of synthetic material or biological tissue used to bridge together the defect between the edge of an incision or a gap in a biological structure (e.g., a vessel wall). Patches are also used after lung surgery to strengthen the repaired lung.
  • Synthetic vascular patches are available from medical device companies such as IMPRA, WL Gore, Sulzer Vascutek, Shelhigh, Bio Nova International, Intervascular and Aesculap for example.
  • Tissue-based vascular patches are available from Biovascular and St Jude Medical. Representative examples of surgical patches are described in U.S. Patent Nos. 5,100,422; 5,104,400; 5,437,900; 5,456,711; 5,641,566; 5,645,915; 6,296,657; and 6,322,593.
  • Vascular patches as described herein can be, among other uses, during vascular surgery to repair blood vessels.
  • Inflammation occurs when cells of the immune system are activated in response to foreign agents or antigens.
  • Leucocytes release lysosomal enzymes.
  • Arachidonic acid is synthesized and eicosanoids, kinins, complement components and histamine are released.
  • Cytokines have a powerful chemotactic effect on eosinophils, neutrophils and macrophages. They also promote local hyperemia and vascular permeability.
  • Superoxide anion is formed by the reduction of molecular oxygen, which stimulates the production of other reactive molecules such as hydrogen peroxide and hydroxyl radicals. The interaction of these substances with arachidonic acid results in the generation of more chemotatic substances, thus perpetuating the inflammatory process.
  • Anti-inflammatory drugs inhibit one or several of the processes described above thus interfering with the inflammatory reaction.
  • anti-inflammatory drugs include but are not limited to nonsteroidal inflammatory drugs such as aspirin, ibuprofen, naproxen, fenoprofen, indomethacin, sulindac, meclofenamate, mefenamic acid, tolmetin, phenylbutazone, piroxicam, diflunisal apazone carprofen, flurbiprofen, diclofenac, ketoprofen; slow- acting anti-inflammatory drugs such as chloroquinine, hydroxychloroquinine, gold, penicillamine, levamisole; glucocorticoid drugs such as hydrocortisone, cortisone, dexamethasone, prednisone, fluocortolone, triamcinolone, fludrocortisone; statins such as pravastatin, fluvastatin, simvastatin, lovastatin; thromboxane inhibitors such as triazolopyrimidine;
  • the anti-inflammatory potential of agents can be assessed by studying their inhibition of cyclooxygenase-1 and cyclooxygenase-2 (Everts et al., 2000. Clin. Rheumatol. 19: 331-343), their inhibition of phospholipase activity and prostaglandine release (Sampey et al., Mediators Inflamm. 9:125-132, 2000), their inhibition of tumor necrosis factor-alpha (TNF- ⁇ ) synthesis and secretion (Joyce et al., Inflamm Res.
  • Hemostasis is the spontaneous arrest of bleeding from a damaged blood vessel.
  • the normal vascular endothelium is not thrombogenic and circulating blood platelets and clotting factors do not adhere to it.
  • platelets adhere to the site of injury. As platelets become activated, they secrete agents such as ADP and prostaglandins that enhance recruitment and adherence of other platelets. The resulting growing thrombus of aggregated platelets reduces blood flow and triggers fibrin formation. The fibrin network reinforces the initial platelet plug thus ensuring long-term hemostasis.
  • platelets release growth factors such as platelet-derived growth factor that promote healing of the damage blood vessel.
  • Anti-platelet agents are compounds that interfere with platelet activation, adhesion or secretion and thus inhibit thrombus formation.
  • anti-platelet agents include but are not limited to, aspirin (Awtry, 2000, Circulation, 101 : 1206- 1218), ADP receptor antagonists such as clopidogrel, ticlopidine and their active metabolites (Coukell and Markham, 1997 Drugs 54: 745-750; Muller et al., 2000 Circulation 101: 590-593; Bertrand et al., 2000 Circulation 102: 624-629; Quinn and Fitzgerald, 1999 Circulation 100: 1667-1672), serotonin receptor antagonists (Herbert et al., 1993 Thromb.
  • platelet glycoprotein receptor antagonists such as abciximab, tirofiban, eptifibatide, lamifiban, orbofiban, roxifiban, sibrafiban, lefradaf ⁇ ban, xemilofiban and their active metabolites
  • platelet glycoprotein receptor antagonists such as abciximab, tirofiban, eptifibatide, lamifiban, orbofiban, roxifiban, sibrafiban, lefradaf ⁇ ban, xemilofiban and their active metabolites
  • statins such as pravastatin, fluvastatin, simvastatin, lovastatin (Igarashi et al., 1997 British Journal of Pharmacology 120: 1172-1178)
  • cAMP phosphodiesterase inhibitors such as cilostazol (Kimura et al., 1985 Drug Res.
  • nitric oxyde donors such as molsidomine, linsidomine, L-arginine 0, alpha-adrenergic antagonists such as dihydrogeneted ergopeptines, phentolamine, and yohimbin.
  • the antiplatelet activity of agents can be assayed by monitoring in vitro platelet aggregation after activation by agonists using turbidimetry or radiolabeled platelets.
  • In vivo quantification of platelet aggregation can be performed with radiolabeled platelets in models of arterio-venous shunts, stent placement and graft implantation.
  • In vivo antiplatelet activity can also be assessed by monitoring arterial temperature distal to thrombus formation and by determining bleeding time. (Hebert et al., 1998 Thromb. Haemost.
  • Anticoagulants Blood coagulates by the transformation of soluble fibrinogen into insoluble fibrin. More than a dozen circulating proteins interact in a cascading series of proteolytic reactions. At each step, an inactive clotting factor undergoes proteolytic cleavage and become an active protease. This protease activates the next clotting factor. The end product of the coagulation cascade is the formation of a solid fibrin clot. Anticoagulants are agents that interfere with the coagulation cascade and inhibit the formation of fibrin.
  • anticoagulants include, but are not limited to, warfarin and coumarin anticoagulants, tissue factor pathway inhibitor, active-site inactivated factor Vila ( DEGR-VUa), tick anticoagulant peptide, antithrombin agents such as heparin, low-molecular-weight-heparin, hirudin, bivalirudin (Jang et al., 1995 Circulation 92: 3041-3050), retinoids such as all-trans-retinoic acid.
  • warfarin and coumarin anticoagulants tissue factor pathway inhibitor, active-site inactivated factor Vila ( DEGR-VUa), tick anticoagulant peptide, antithrombin agents such as heparin, low-molecular-weight-heparin, hirudin, bivalirudin (Jang et al., 1995 Circulation 92: 3041-3050), retinoids such as all-trans-retinoic acid.
  • the anticoagulation activity of agents can be assayed by measuring the activated partial thromboplastin time and the prothrombin time (Freund et al., 1993 Thrombosis and Hemostasis 69: 515-521; Jang et al., 1995 Circulation 92: 3041-3050).
  • Fibrinolytic agents Fibrinolysis is a naturally occurring process that removes unneeded clots once healing has occurred.
  • the critical step in this system is the transformation of plasminogen into plasmin, a protein-digesting enzyme. Plasmin dissolves thrombus by lysing fibrin.
  • Fibrinolytic drugs promote the formation of plasmin.
  • fibrinolytic agents include, but are not limited to, tissue plasminogen activator, urokinase, streptokinase, staphylokinase, anistreplase, reteplase, lanoteplase (Valji, 2000 JVIR 11: 411-420) retinoids such as all-trans-retinoic acid.
  • Fibrinolysis activity of agents can be assayed by monitoring the dissolution of thrombus labeled with radioactive fibrin (Herbert et al., 1993 Thrombosis and Haemostasis 69: 268-271). Cell Cycle Inhibitors.
  • cell cycle inhibitory agents can be utilized, either with or without a carrier (e.g., a polymer or ointment or vector), in order to treat or prevent a hyperproliferative disease.
  • a carrier e.g., a polymer or ointment or vector
  • cell cycle inhibitory agents include taxanes (e.g., paclitaxel (discussed in more detail below) and docetaxel) (Schiff et al., Nature 277:665-667, 1979; Long and Fairchild, Cancer Research 54:4355-4361, 1994; Ringel and Horwitz, J. Nat'l Cancer Inst. 55(4):288-291, 1991; Pazdur et al, Cancer Treat. Rev.
  • Keto-aldehyde-amine addition products and method of making same U.S. Patent No. 4,066,650, Jan 3, 1978), nitroimidazole (K.C. Agrawal and M. Sakaguchi. Nitroimidazole radiosensitizers for Hypoxic tumor cells and compositions thereof.
  • U.S. Patent No. 4,462,992, Jul. 31, 1984 5-substituted-4- nitroimidazoles (Adams et al, Int. J. Radiat. Biol Relat. Stud. Phys., Chem. Med. 40(2):153-61, 1981), SR-2508 (Brown et al, Int. J. Radiat. Oncol, Biol. Phys.
  • camptothecin Ewend M.G. et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Research 5 ⁇ 5(22):5217-5223, 1996) and paclitaxel (Tishler R.B. et al. Taxol: a novel radiation sensitizer. International Journal of Radiation Oncology and Biological Physics 22(3):613-617, 1992).
  • a number of the above-mentioned cell cycle inhibitors also have a wide variety of analogues and derivatives, including, but not limited to, cisplatin, cyclophosphamide, misonidazole, tiripazamine, nitrosourea, mercaptopurine, methotrexate, flurouracil, epirubicin, doxorubicin, vindesine and etoposide.
  • Analogues and derivatives include (CPA) 2 Pt[DOLYM] and (DACH)Pt[DOLYM] cisplatin (Choi et al, Arch. Pharmacal Res.
  • 6-mercaptopurine (6-MP) (Kashida et al, Biol. Pharm. Bull. 18(11): 1492-7, 1995), 7,8- polymethyleneimidazo-l,3,2-diazaphosphorines (Nilov et al, Mendeleev Commun. 2:67, 1995), azathioprine (Chifotides et al, J. Inorg. Biochem. 5 ⁇ " (4):249-64, 1994), methyl-D-glucopyranoside mercaptopurine derivatives (Da Silva et al, Eur. J. Med. Chem.
  • N-( -aminoacyl) methotrexate derivatives Cheung et al, Pteridines 3(l-2):101-2, 1992
  • biotin methotrexate derivatives Fean et al, Pteridines 3(l-2):131-2, 1992
  • D-glutamic acid or D-erythrou, threo-4- fiuoroglutamic acid methotrexate analogues McGuire et al, Biochem. Pharmacol.
  • the cell cycle inhibitor is taxane such as paclitaxel.
  • taxanes are compounds which disrupts mitosis (M-phase) by binding to tubulin to form abnormal mitotic spindles or an analogue or derivative thereof.
  • Paclitaxel the most recognized member of the taxane family is a highly derivatized dite ⁇ enoid (Wani et al, J. Am. Chem. Soc. 93:2325, 1971) which has been obtained from the harvested and dried bark of Taxus brevifolia (Pacific Yew) and Taxomyces Andreanae and Endophytic Fungus of the Pacific Yew (Stierle et al, Science 60:214-216, 1993).
  • “Paclitaxel” (which should be understood herein to include formulations, prodrugs, analogues and derivatives such as, for example, TAXOL ® , TAXOTERE ® , docetaxel, 10-desacetyl analogues of paclitaxel and 3'N-desbenzoyl-3'N-t-butoxy carbonyl analogues of paclitaxel) may be readily prepared utilizing techniques known to those skilled in the art (see, e.g., Schiff et al, Nature 277:665-667, 1979; Long and Fairchild, Cancer Research 54:4355-4361, 1994; Ringel and Horwitz, J. N ⁇ tY Cancer Inst.
  • paclitaxel derivatives or analogues include 7-deoxy-docetaxol, 7,8-cyclopropataxanes, N-substituted 2-azetidones, 6,7-epoxy paclitaxels, 6,7-modified paclitaxels, 10-desacetoxytaxol, 10-deacetyltaxol (from 10- deacetylbaccatin TH), phosphonooxy and carbonate derivatives of taxol, taxol 2',7- di(sodium 1 ,2-benzenedicarboxylate, 10-desacetoxy- 11 , 12-dihydrotaxol- 10,12(18)- diene derivatives, 10-desacetoxytaxol, Protaxol (2'-and/or 7-O-ester derivatives ), (2'- and/or 7-O-carbonate derivatives), asymmetric synthesis of taxol side chain, fluoro taxols, 9-deoxotaxane, (13-acet)
  • the Cell Cycle Inhibitor is a taxane having the formula (CI): where the gray-highlighted portions may be substituted and the non-highlighted portion is the taxane core.
  • a side-chain (labeled "A" in the diagram ) is desirably present in order for the compound to have good activity as a Cell Cycle Inhibitor.
  • Examples of compounds having this structure include paclitaxel (Merck Index entry 7117), docetaxol (Taxotere, Merck Index entry 3458), and 3'-desphenyl-3'-(4-ntiropheny ⁇ )-N-debenzoyl- N-(t-butoxycarbonyl)- 10-deacetyltaxol.
  • suitable taxanes such as paclitaxel and its analogs and derivatives are disclosed in Patent No. 5,440,056 as having the structure (C2): wherein X may be oxygen (paclitaxel), hydrogen (9-deoxy derivatives), thioacyl, or dihydroxyl precursors; R ⁇ is selected from paclitaxel or taxotere side chains or alkanoyl of the formula (C3)
  • R 7 is selected from hydrogen, alkyl, phenyl, alkoxy, amino, phenoxy (substituted or unsubstituted);
  • R 8 is selected from hydorgen, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, phenyl (substituted or unsubstituted), alpha or beta-naphthyl;
  • R 9 is selected from hydrogen, alkanoyl, substituted alkanoyl, and aminoalkanoyl; where substitutions refer to hydroxyl, sulfhydryl, allalkoxyl, carboxyl, halogen, thioalkoxyl, N,N-dimethylamino, alkylamino, dialkylamino, nitro, and -OSO 3 H, and/or may refer to groups containing such substitutions;
  • R is selected from hydrogen or oxygen-containing groups, such as hydrogen, hydroxyl, alkoyl, alkanoy
  • WO 93/10076 discloses that the taxane nucleus may be substituted at any position with the exception of the existing methyl groups.
  • the substitutions may include, for example, hydrogen, alkanoyloxy, alkenoyloxy, aryloyloxy.
  • oxo groups may be attached to carbons labeled 2, 4, 9, 10.
  • an oxetane ring may be attached at carbons 4 and 5.
  • an oxirane ring may be attached to the carbon labeled 4.
  • the taxane-based Cell Cycle Inhibitor useful in the present invention is disclosed in U.S. Patent 5,440,056, which discloses 9-deoxo taxanes. These are compounds lacking an oxo group at the carbon labeled 9 in the taxane structure shown above (formula C4).
  • the taxane ring may be substituted at the carbons labeled 1, 7 and 10 (independently) with H, OH, O-R, or O-CO-R where R is an alkyl or an aminoalkyl.
  • it may be substituted at carbons labeled 2 and 4 (independently) with aryol, alkanoyl, aminoalkanoyl or alkyl groups.
  • the side chain of formula (C3) may be substituted at R 7 and Rs (independently) with phenyl rings, substituted phenyl rings, linear alkanes/alkenes, and groups containing H, O or N.
  • R 9 may be substituted with H, or a substituted or unsubstituted alkanoyl group.
  • Taxanes in general, and paclitaxel is particular, is considered to function as a Cell Cycle Inhibitor by acting as a anti-microtuble agent, and more specifically as a stabilizer.
  • the Cell Cycle inhibitor is a Vinca Alkaloid.
  • Vinca alkaloids have the following general structure. They are indole-dihydroindole dimers. dihydroindole
  • R] can be a formyl or methyl group or alternately H.
  • Ri could also be an alkyl group or an aldehyde-substituted alkyl (e.g., CH 2 CHO).
  • R 2 is typically a CH 3 or NH 2 group. However it can be alternately substituted with a lower alkyl ester or the ester linking to the dihydroindole core may be substituted with C(O)-R where R is NH 2 , an amino acid ester or a peptide ester.
  • R 3 is typically C(O)CH 3 , CH 3 or H.
  • a protein fragment may be linked by a bifunctional group such as maleoyl amino acid.
  • R 3 could also be substituted to form an alkyl ester which may be further substituted.
  • R 4 may be - CH 2 - or a single bond.
  • R 5 and R$ may be H, OH or a lower alkyl, typically -CH 2 CH 3 .
  • Re and R may together form an oxetane ring.
  • R 7 may alternately be H.
  • Further substitutions include molecules wherein methyl groups are substituted with other alkyl groups, and whereby unsaturated rings may be derivatized by the addition of a side group such as an alkane, alkene, alkyne, halogen, ester, amide or amino group.
  • Exemplary Vinca Alkaloids are vinblastine, vincristine, vincristine sulfate, vindesine, and vinorelbine, having the structures:
  • Analogs typically require the side group (shaded area) in order to have activity. These compounds are believed to act as Cell Cycle Inhibitors by functioning as anti-microtubule agents, and more specifically to inhibit polymerization.
  • the Cell Cycle Inhibitor is Camptothecin, or an analog or derivative thereof. Camptothecins have the following general structure.
  • X is typically O, but can be other groups, e.g. , NH in the case of 21-lactam derivatives.
  • R ⁇ is typically H or OH, but may be other groups, e.g., a terminally hydroxylated C 1-3 alkane.
  • R 2 is typically H or an amino containing group such as (CH 3 ) 2 NHCH 2 , but may be other groups e.g., NO 2 , NH 2 , halogen (as disclosed in, e.g., U.S. Patent 5,552,156) or a short alkane containing these groups.
  • R 3 is typically H or a short alkyl such as C 2 H 5 .
  • j is typically H but may be other groups, e.g., a methylenedioxy group with Exemplary camptothecin compounds include topotecan, irinotecan
  • CPT-11 9-aminocamptothecin, 21-lactam-20(S)-camptothecin, 10,11- methylenedioxycamptothecin, SN-38, 9-nitrocamptothecin, lO-hydroxycamptothecin.
  • Exemplary compounds have the structures:
  • Camptothecins have the five rings shown here.
  • the ring labeled E must be intact (the lactone rather than carboxylate form) for maximum activity and minimum toxicity.
  • These compounds are useful to as Cell Cycle Inhibitors, where they function as Topoisomerase I Inhibitors and/or DNA cleavage agents.
  • the Cell Cycle Inhibitor is a Podophyllotoxin, or a derivative or an analog thereof.
  • Exemplary compounds of this type are Etoposide or Teniposide, which have the following structures: These compounds are believed to function as Cell Cycle Inhibitors by being Topoisomerase H Inhibitors and/or by DNA cleaving agents.
  • the Cell Cycle Inhibitor is an Anthracycline.
  • Anthracyclines have the following general structure, where the R groups may be a variety of organic groups:
  • R is CH 3 or
  • R 2 is daunosamine or H
  • R 3 and R 4 are independently one of OH, NO 2 , NH 2 , F,
  • R 5- are all H or R 5 and Re are H and R 7 and R 8 are alkyl or halogen, or vice versa: R 7 and R 8 are H and R 5 and Re are alkyl or halogen.
  • R 2 may be a conjugated peptide.
  • R 5 may be OH or an ether linked alkyl group.
  • R ⁇ may also be linked to the anthracycline ring by a group other than C(O), such as an alkyl or branched alkyl group having the C(O) linking moiety at its end, such as -CH 2 CH(CH 2 -X)C(O)-R ⁇ , wherein X is H or an alkyl group (see, e.g., U.S. Patent 4,215,062).
  • R 3 may have the following structure: in which R 9 is OH either in or out of the plane of the ring, or is a second sugar moiety such as R 3 . may be H or form a secondary amine with a group such as an aromatic group, saturated or partially saturated 5 or 6 membered heterocyclic having at least one ring nitrogen (see U.S. Patent 5,843,903).
  • R ⁇ 0 may be derived from an amino acid, having the structure -C(O)CH(NHR ⁇ )(R 12 ), in which R ⁇ is H, or forms a C 3- membered alkylene with R 12 .
  • Rj 2 may be H, alkyl, aminoalkyl, amino, hydroxy, mercapto, phenyl, benzyl or methylthio (see U.S. Patent 4,296,105).
  • Anthracycline are Doxorubicin, Daunorubicin, Idarubicin, Epirubicin, Pirarubicin, Zorubicin, and Carubicin.
  • Suitable compounds have the structures:
  • Anthracyclines are Anthramycin, Mitoxantrone, Menogaril, Nogalamycin, Aclacinomycin A, Olivomycin A, Chromomycin A 3 , and Plicamycin having the structures:
  • Chromomy ⁇ n A, COCH, CH, COCH, CH, Plicamycin H H H CH are believed to function as Cell Cycle Inhibitors by being Topoisomerase Inhibitors and/or by DNA cleaving agents.
  • the Cell Cycle Inhibitor is a Platinum compound.
  • suitable platinum complexes may be of Pt(H) or Pt(IV) and have this basic structure: wherein X and Y are anionic leaving groups such as sulfate, phosphate, carboxylate, and halogen; Ri and R 2 are alkyl, amine, amino alkyl any may be further substituted, and are basically inert or bridging groups.
  • X and Y are anionic leaving groups such as sulfate, phosphate, carboxylate, and halogen
  • Ri and R 2 are alkyl, amine, amino alkyl any may be further substituted, and are basically inert or bridging groups.
  • Z ⁇ and Z 2 are non- existent.
  • Z ⁇ and Z 2 may be anionic groups such as halogen, hydroxy, carboxylate, ester, sulfate or phosphate. See, e.g., U.S. Patent Nos. 4,588,831 and 4,
  • Suitable platinum complexes may contain multiple Pt atoms. See, e.g., U.S. Patent Nos. 5,409,915 and 5,380,897.
  • Exemplary Platinum compound are Cisplatin, Carboplatin, Oxahplatin, and Miboplatin having the structures:
  • the Cell Cycle Inhibitor is a Nitrosourea.
  • Nitrosourease have the following general structure (C5), where typical R groups are shown below.
  • R groups include cyclic alkanes, alkanes, halogen substituted groups, sugars, aryl and heteroaryl groups, phosphonyl and sulfonyl groups.
  • R may suitably be CH 2 -C(X)(Y)(Z), wherein X and Y may be the same or different members of the following groups: phenyl, cyclyhexyl, or a phenyl or cyclohexyl group substituted with groups such as halogen, lower alkyl (C 1- ), trifluore methyl, cyano, phenyl, cyclohexyl, lower alkyloxy (C ⁇ - ).
  • Ri and R 2 may be the same or different members of the following group: lower alkyl (C ) and benzyl, or together Ri and R may form a saturated 5 or 6 membered heterocyclic such as pyrrolidine, piperidine, morfoline, thiomorfoline, N-lower alkyl piperazine, where the heterocyclic may be optionally substituted with lower alkyl groups.
  • R and R' of formula (C5) may be the same or different, where each may be a substituted or unsubstituted hydrocarbon having 1-10 carbons. Substitutions may include hydrocarbyl, halo, ester, amide, carboxylic acid, ether, thioether and alcohol groups. As disclosed in U.S. Patent No.
  • R of formula (C5) may be an amide bond and a pyranose structure (e.g., Methyl 2 , -[N-[N-(2-chloroethyl)-N-nitroso-carbamoyl]-glycyl]amino-2 , -deoxy- ⁇ -D- glucopyranoside).
  • R of formula (C5) may be an alkyl group of 2 to 6 carbons and may be substituted with an ester, sulfonyl, or hydroxyl group. It may also be substituted with a carboxylica acid or CONH 2 group.
  • Exemplary Nitrosourea are BCNU (Carmustine), Methyl-CCNU (Semustine), CCNU (Lomustine), Ranimustine, Nimustine, Chlorozotocin, Fotemustine, Streptozocin, and Streptozocin, having the structures:
  • nitrosourea compounds are believed to function as Cell Cycle Inhibitor by binding to DNA, that is, by functioning as DNA alkylating agents.
  • the Cell Cycle Inhibitor is a Nitroimidazole, where exemplary Nitioimidazoles are Metronidazole, Benznidazole, Etanidazole, and Misonidazole, having the structures:
  • Suitable nitroimidazole compounds are disclosed in, e.g., U.S. Patent Nos. 4,371,540 and 4,462,992.
  • the Cell Cycle Inhibitor is a Folic acid antagonist, such as Methotrexate or derivatives or analogs thereof, including Edatrexate, Trimetrexate, Raltitrexed, Piritrexim, Denopterin, Tomudex, and Pteropterin.
  • Methotrexate analogs have the following general structure:
  • R group may be selected from organic groups, particularly those groups set forth in U.S. Patent Nos. 5,166,149 and 5,382,582.
  • Ri may be N
  • R 2 may be N or C(CH 3 )
  • R 3 and R 3 1 may H or alkyl, e.g., CH 3
  • R t may be a single bond or NR, where R is H or alkyl group.
  • R 5 , 6 , 8 may be H, OCH 3 , or alternately they can be halogens or hydro groups.
  • R 7 is a side chain of the general structure:
  • the carboxyl groups in the side chain may be esterified or form a salt such as a Zn 2+ salt.
  • R 9 and R 10 can be NH 2 or may be alkyl substituted.
  • Exemplary folic acid antagonist compounds have the structures:
  • the Cell Cycle Inhibitor is a Cytidine Analog, such as Cytarabine or derivatives or analogs thereof, including Enocitabine, FMdC ((E(-2'- deoxy-2'-(fluoromethylene)cytidine), Gemcitabine, 5-Azacitidine, Ancitabine, and 6- Azauridine.
  • Cytidine Analog such as Cytarabine or derivatives or analogs thereof, including Enocitabine, FMdC ((E(-2'- deoxy-2'-(fluoromethylene)cytidine), Gemcitabine, 5-Azacitidine, Ancitabine, and 6- Azauridine.
  • Exemplary compounds have the structures:
  • the Cell Cycle Inhibitor is a Pyrimidine analog.
  • the Pyrimidine analogs have the general structure: wherein positions 2', 3' and 5' on the sugar ring (R 2 , R 3 and R t , respectively) can be H, hydroxyl, phosphoryl (see, e.g., U.S. Patent 4,086,417) or ester (see, e.g., U.S. Patent 3,894,000).
  • Esters can be of alkyl, cycloalkyl, aryl or heterocyclo/aryl types.
  • the 2' carbon can be hydroxylated at either R 2 or R 2 ', the other group is H.
  • the 2' carbon can be substituted with halogens e.g., fluoro or difluoro cytidines such as Gemcytabine.
  • the sugar can be substituted for another heterocyclic group such as a furyl group or for an alkane, an alkyl ether or an amide linked alkane such as C(O)NH(CH 2 ) 5 CH 3 .
  • the 2° amine can be substituted with an aliphatic acyl (Ri) linked with an amide (see, e.g., U.S.
  • R 5 in the pyrimidine ring may be N or CR, where R is H, halogen containing groups, or alkyl ( ee, e.g., U.S. Patent No. 4,086,417).
  • R 8 is H or R 7 and R 8 together can form a double bond or R 8 can be X, where X is:
  • the Cell Cycle Inhibitor is a Fluoro-pyrimidine Analog, such as 5-Fluorouracil, or an analog or derivative thereof, including Carmofur, Doxifluridine, Emitefur, Tegafur, and Floxuridine.
  • exemplary compounds have the structures:
  • Fluoropyrimidine Analogs include 5-FudR (5-fluoro- deoxyuridine), or an analog or derivative thereof, including 5-iododeoxyuridine (5-fluoro-deoxyuridine).
  • the Cell Cycle Inhibitor is a Purine Analog.
  • Purine analogs have the following general structure:
  • X is typically carbon;
  • R ⁇ is H, halogen, amine or a substituted phenyl;
  • R 2 is H, a primary, secondary or tertiary amine, a sulfur containing group, typically -SH, an alkane, a cyclic alkane, a heterocyclic or a sugar;
  • R 3 is H, a sugar (typically a furanose or pyranose structure), a substituted sugar or a cyclic or heterocyclic alkane or aryl group. See, e.g., U.S. Patent No. 5,602,140 for compounds of this type.
  • X-R2 is -CH 2 CH(OH)-.
  • a second carbon atom is inserted in the ring between X and the adjacent nitrogen atom.
  • the X-N double bond becomes a single bond.
  • N signifies nitrogen and V, W, X, Z can be either carbon or nitrogen with the following provisos.
  • Ring A may have 0 to 3 mtiogen atoms in its structure. If two nitrogens are present in ring A, one must be in the W position. If only one is present, it must not be in the Q position. V and Q must not be simultaneously nitrogen. Z and Q must not be simultaneously nitrogen. If Z is nitrogen, R 3 is not present.
  • R ⁇ -3 are independently one of H, halogen, C ⁇ - alkyl, C ⁇ - alkenyl, hydroxyl, mercapto, C ⁇ -7 alkylthio, C ⁇ -7 alkoxy, C 2-7 alkenyloxy, aryl oxy, nitro, primary, secondary or tertiary amine containing group.
  • R 5-8 are H or up to two of the positions may contain independently one of OH, halogen, cyano, azido, substituted amino, R 5 and R 7 can together form a double bond.
  • Y is H, a C ⁇ - alkylcarbonyl, or a mono- di or tri phosphate.
  • Exemplary suitable purine analogs include 6-Mercaptopurine, Thiguanosine, Thiamiprine, Cladribine, Fludaribine, Tubercidin, Puromycin, PentoxyfiUine; where these compounds may optionally be phosphorylated.
  • Exemplary compounds have the structures:
  • the Cell Cycle Inhibitor is a Nitrogen Mustard.
  • Nitrogen Mustards are known and are suitably used as a Cell Cycle Inhibitor in the present invention.
  • Suitable nitrogen mustards are also known as cyclophosphamides.
  • a preferred nitrogen mustard has the general structure:
  • A is: or -CH 3 or other alkane, or chloronated alkane, typically CH 2 CH(CH 3 )C1, or a polycyclic group such as B, or a substituted phenyl such as C or a heterocyclic group such as D.
  • R 1-2 are H or CH 2 CH 2 C1;
  • R 3 is H or oxygen-containing groups such as hydroperoxy; and
  • R 4 can be alkyl, aryl, heterocyclic.
  • cyclic moiety need not be intact. See, e.g., U.S. Patent Nos. 5,472,956, 4,908,356, 4,841,085 that describe the following type of structure: wherein Ri is H or CH 2 CH 2 C1, and R 2-6 are various substituent groups.
  • Exemplary nitrogen mustards include methylchloroethamine, and analogs or derivatives thereof, including methylchloroethamine oxide hydrohchloride, Novembichin, and Mannomustine (a halogenated sugar).
  • Exemplary compounds have the structures:
  • the Nitrogen Mustard may be Cyclophosphamide, Ifosfamide, Perfosfamide, or Torofosfamide, where these compounds have the structures:
  • the Nitrogen Mustard may be Estramustine, or an analog or derivative thereof, including Phenesterine, Prednimustine, and Estramustine PO 4 .
  • suitable nitrogen mustard type Cell Cycle Inhibitors of the present invention have the structures:
  • the Nitrogen Mustard may be Chlorambucil, or an analog or derivative thereof, including Melphalan and Chlormaphazine.
  • suitable nitrogen mustard type Cell Cycle Inhibitors of the present invention have the structures:
  • the Nitrogen Mustard may be Uracil Mustard, which has the structure:
  • the Nitrogen Mustards are believed to function as Cell Cycle Inhibitors by serving as alkylating agents for DNA. Nitrogen Mustards have been shown useful in the treatment of cell proliferative disorders including, for example, small cell lung, breast, cervical, head and neck, prostate, retinoblastoma, and soft tissue sarcoma.
  • the Cell Cycle Inhibitor of the present invention may be a Hydroxyurea. Hydroxyureas have the following general structure:
  • Suitable Hydroxyureas are disclosed in, for example, U.S. Patent No. 6,080,874, wherein R ! is: and R 2 is an alkyl group having 1-4 carbons and R 3 is one of H, acyl, methyl, ethyl, and mixtures thereof, such as a methylether.
  • R ⁇ is a cycloalkenyl group, for example N-[3-[5-(4- fluorophenylthio)-furyl]-2-cyclopenten-l-yl]N-hydroxyurea;
  • R 2 is H or an alkyl group having 1 to 4 carbons and R 3 is H;
  • X is H or a cation.
  • Suitable Hydroxyureas are disclosed in, e.g., U.S. Patent No. 5,066,658, wherein R and R 3 together with the adjacent nitrogen form: wherein m is 1 or 2, n is 0-2 and Y is an alkyl group.
  • the hydroxy urea has the structure:
  • Hydroxyurea Hydroxyureas are believed to function as Cell Cycle Inhibitors by serving to inhibit DNA synthesis.
  • the Cell Cycle Inhibitor is a Belomycin, such as Bleomycin A 2 , which have the structures:
  • the Cell Cycle Inhibitor is a Mytomycin, such as
  • Mitomycin C or an analog or derivative thereof, such as Porphyromycin.
  • Suitable compounds have the structures:
  • the Cell Cycle Inhibitor is an Alkyl sulfonate, such as Busulfan, or an analog or derivative thereof, such as Treosulfan, Improsulfan, Piposulfan, and Pipobroman.
  • Exemplary compounds have the structures:
  • the Cell Cycle Inhibitor is a Benzamide.
  • the Cell Cycle Inhibitor is a Nicotinamide.
  • X is either O or S; A is commonly NH 2 or it can be OH or an alkoxy group; B is N or C-R A , where t is H or an ether-linked hydroxylated alkane such as OCH 2 CH 2 OH, the alkane may be linear or branched and may contain one or more hydroxyl groups. Alternately, B may be N-R 5 in which case the double bond in the ring involving B is a single bond. R 5 may be H, and alkyl or an aryl group (see, e.g., U.S. Patent No.
  • R 2 is H, OR ⁇ , SRe or NHRe, where Re is an alkyl group
  • R 3 is H, a lower alkyl, an ether linked lower alkyl such as -O-Me or -O-Ethyl (see, e.g., U.S. Patent No. 5,215,738).
  • Suitable Benzamide compounds have the structures:
  • R alkyl group where additional compounds are disclosed in U.S. Patent No. 5,215,738, (listing some 32 compounds).
  • Suitable Nicotinamide compounds have the structures:
  • R alkyl or aryl group and U.S. Patent No. 4,258,052 (listing some 46 compounds, e.g., l-methyl-6-keto-l,6- dihydronicotinic acid).
  • the Cell Cycle Inhibitor is a Tetrazine Compound, such as Temozolomide, or an analog or derivative thereof, including dacarbazine.
  • Suitable compounds have the structures:
  • Tetrazine Compound is Procarbazine, including HCI and HBr salts, having the structure:
  • the Cell Cycle Inhibitor is Actinomycin D, or other members of this family, including Dactinomycin, Actinomycin Ci, Actinomycin ' C 2 , Actinomycin C 3 , and Actinomycin ⁇ .
  • Suitable compounds have the structures:
  • the Cell Cycle Inhibitor is an Aziridine compound, such as Benzodepa, or an analog or derivative thereof, including Meturedepa, Uredepa, and Carboquone.
  • Suitable compounds have the structures:
  • the Cell Cycle Inhibitor is Halogenated Sugar, such as Mitolactol, or an analog or derivative thereof, including Mitobronitol and Mannomustine.
  • Suitable compounds have the structures:
  • the Cell Cycle Inhibitor is a Diazo compound, such as Azaserine, or an analog or derivative thereof, including 6-diazo-5-oxo-L-norleucine and 5-diazouracil (also a pyrimidine analog).
  • Suitable compounds have the structures:
  • Other compounds that may serve as Cell Cycle Inhibitors according to the present invention are Pazelliptine; Wortmannin; Metoclopramide; RSU; Buthionine sulfoxime; Tumeric; Curcumin; AG337, a thymidylate synthase inhibitor; Levamisole; Lentinan, a polysaccharide; Razoxane, an EDTA analog; Indomethacin; Chlorpromazine; ⁇ and ⁇ interferon; MnBOPP; Gadolinium texaphyrin; 4-amino-l,8- naphthalimide; Staurosporine derivative of CGP; and SR-2508.
  • the Cell Cycle Inhibitor is a DNA alkylating agent.
  • the Cell Cycle Inhibitor is an anti-microtubule agent.
  • the Cell Cycle Inhibitor is a Topoisomerase inhibitor.
  • the Cell Cycle Inhibitor is a DNA cleaving agent.
  • the Cell Cycle Inhibitor is an antimetabolite.
  • the Cell Cycle Inhibitor functions by inhibiting adenosine deaminase (e.g., as a purine analog).
  • the Cell Cycle Inhibitor functions by inhibiting purine ring synthesis and/or as a nucleotide interconversion inhibitor (e.g., as a purine analog such as mercaptopurine).
  • the Cell Cycle Inhibitor functions by inhibiting dihydrofolate reduction and/or as a thymidine monophosphate block (e.g., methotrexate).
  • the Cell Cycle Inhibitor functions by causing DNA damage (e.g., Bleomycin).
  • the Cell Cycle Inhibitor functions as a DNA intercalation agent and/or RNA synthesis inhibition (e.g., Doxorubicin).
  • the Cell Cycle Inhibitor functions by inhibiting pyrimidine synthesis (e.g., N-phosphonoacetyl-L-Aspartate). In another aspect, the Cell Cycle Inhibitor functions by inhibiting ribonucleotides (e.g., hydroxyurea). In another aspect, the Cell Cycle Inhibitor functions by inhibiting thymidine monophosphate (e.g., 5 -fluorouracil). In another aspect, the Cell Cycle Inhibitor functions by inhibiting DNA synthesis (e.g., Cytarabine). In another aspect, the Cell Cycle Inhibitor functions by causing DNA adduct formation (e.g., platinum compounds).
  • pyrimidine synthesis e.g., N-phosphonoacetyl-L-Aspartate
  • the Cell Cycle Inhibitor functions by inhibiting ribonucleotides (e.g., hydroxyurea).
  • the Cell Cycle Inhibitor functions by inhibiting thymidine monophosphate
  • the Cell Cycle Inhibitor functions by inhibiting protein synthesis (e.g., L-Asparginase). In another aspect, the Cell Cycle Inhibitor functions by inhibiting micro tubule function (e.g., taxanes). In another aspect, the Cell Cycle Inhibitors acts at one or more of the steps in the biological pathway shown in Figure 1.
  • polypeptides, proteins and peptides, as well as nucleic acids that encode such proteins can also be used therapeutically as cell cycle inhibitors. This is accomplished by delivery by a suitable vector or gene delivery vehicle which encodes a cell cycle inhibitor (Walther & Stein, Drugs ⁇ 50(2):249-71, Aug 2000; Kim et al, Archives of Pharmacal Res. 24(1): 1-15, Feb 2001; and Anwer et al, Critical Reviews in Therapeutic Drug Carrier Systems 17(4):377-424, 2000.
  • Genes encoding proteins that modulate cell cycle include the INK4 family of genes (US 5,889,169; US 6,033,847), ARF-pl9 (US 5,723,313), p 21 WAF1 CIP1 and p27 ⁇ >1 (WO 9513375; WO 9835022), p27 7 ⁇ lu iP r i ⁇ (WO 9738091), p57 7 K Rj IP r 2 z (US 6,025,480), ATM/ATR (WO 99/04266), Gadd 45 (US 5,858,679), Mytl (US 5,744,349), Weel (WO 9949061) smad 3 and smad 4 (US 6,100,032), 14-3-3 ⁇ (WO 9931240), GSK3 ⁇ (Stambolic, N.
  • HDAC-1 Fluorescence-activated adenosine kinase
  • p53 U.S. 5,532,220
  • pSS 1 * 01 US 5.986.078
  • Retinoblastoma EPO 390530
  • NF-1 WO 9200387
  • gene delivery vehicles may be utilized to deliver and express the proteins described herein, including for example, viral vectors such as retioviral vectors (e.g., U.S. Patent Nos. 5,591,624, 5,716,832, 5,817,491, 5,856,185, 5,888,502, 6,013,517, and 6,133,029; as well as subclasses of retioviral vectors such as lentiviral vectors (e.g., PCT Publication Nos.
  • viral vectors such as retioviral vectors (e.g., U.S. Patent Nos. 5,591,624, 5,716,832, 5,817,491, 5,856,185, 5,888,502, 6,013,517, and 6,133,029; as well as subclasses of retioviral vectors such as lentiviral vectors (e.g., PCT Publication Nos.
  • ribozymes or antisense sequences can be utilized as cell cycle inhibitors.
  • One representative example of such inhibitors is disclosed in PCT Publication No. WO 00/32765 (which, as noted above, is incorporated by reference in its entirety).
  • Intimal hyperplasia is due to the migration and proliferation of cells into the intima followed by extracellular matrix secretion.
  • the main cell types responsible for the hyperplastic response in the intima are smooth muscle cells and fibroblasts. Arterioles and capillaries sprout into the intimal plaque to provide nutrients and oxygen, thus allowing the plaque to grow. Intimal plaque growth eventually leads to occlusion of the lumen of the disease blood vessels with accompanying ischemia to the distal tissues.
  • antiproliferative agents may be coated on or otherwise released from a patch.
  • the antiproliferative activity of the agents can be assayed by quantifying cell migration and proliferation in vitro. Antiproliferative activity can also be determined in vivo by morphometric analysis after vascular injury in various animal models (Signore et al., 2001 J. Vase. Interv. Radiol. 12: 79-88; Axel et al., 1997 Circulation 96: 636-645; Gregory et al., 1993 Transplantation 1409-1418; Burke et al., 1999 J. Cardiovasc. Pharm 33: 829-835; Poon et al., 1996 J. Clin. Invest. 2277-2283; Jones et al., 2001, J. Immunol. Methods, 254: 85-98; Gildea et al., 2000 Biotechniques 29: 81-86).
  • the compound or composition may be applied on the patch by itself or in a carrier, which may be either polymeric, or non- polymeric.
  • a carrier which may be either polymeric, or non- polymeric.
  • polymeric carriers include poly (ethylene- vinyl acetate), copolymers of lactic acid and glycolic acid, poly (caprolactone), poly (lactic acid), copolymers of poly (lactic acid) and poly (caprolactone), gelatin, hyaluronic acid, collagen matrices, celluloses and albumen.
  • Suitable carriers include, but are not limited to, ethanol; mixtures of ethanol and glycols (e.g., ethylene glycol or propylene glycol); mixtures of ethanol and isopropyl myristate or ethanol, isopropyl myristate and water (e.g., 55:5:40); mixtures of ethanol and mecanicol or D-limonene (with or without water); glycols (e.g., ethylene glycol or propylene glycol) and mixtures of glycols such as propylene glycol and water, phosphatidyl glycerol, dioleoylphosphatidyl glycerol, Transcutol®, or terpinolene; mixtures of isopropyl myristate and l-hexyl-2-pyrrolidone, N-dodecyl-2-piperidinone or l-hexyl-2- pyrrolidone.
  • Other representative examples of polymer formulations are described
  • Patches may be coated with compositions of the present invention in a variety of manners, including for example: (a) by directly affixing to the patch a formulation (e.g., by either spraying the stent with a polymer/drug film, or by dipping the stent into a polymer/drug solution), (b) by coating the patch with a substance such as a hydrogel which will in turn absorb the composition, (c) by interweaving formulation-coated thread (or the polymer itself formed into a thread) into the patch structure, (d) by inserting the patch into a sleeve or mesh which is comprised of, or coated with, a formulation, or (e) constructing the patch itself with a composition.
  • a formulation e.g., by either spraying the stent with a polymer/drug film, or by dipping the stent into a polymer/drug solution
  • a substance such as a hydrogel which will in turn absorb the composition
  • a substance such as
  • the composition should firmly adhere to the patch during storage and at the time of implantation, and should not be dislodged from the patch when it is sutured to the blood vessel.
  • the composition should also preferably not degrade during storage, prior to implantation, or when warmed to body temperature after implantation inside the body.
  • it should preferably coat the patch smoothly and evenly, with a uniform distribution of agents while not changing the patch shape.
  • the formulation should be applied to only parts of the patch, leaving the rest of the patch uncoated, for example: (a) only the luminal side of the patch is coated, (b) only the edge of the patch is coated, (c) only one end of the patch is coated, (d) a stripe is left uncoated around the patch (e) part of the patch is coated with one agent and the rest of the patch is coated with another agent.
  • the composition should provide a predictable, prolonged release of the factor into the surrounding tissue for 1 to 12 months after implantation.
  • the composition should provide a predictable, slow release of the factor into the surrounding tissue for 1 to 10 years after implantation.
  • the composition should provide a predictable, prolonged release of the factor into the surrounding tissue for 1 to 4 weeks after implantation.
  • the composition should provide a predictable, fast release of the factor into the surrounding tissue for 1 to 7 days after implantation.
  • the composition should provide a predictable, fast release of the factor into the surrounding tissue for 1 to 24 hours after implantation.
  • the composition is not released into the sunounding tissue. Its presence on the patch forms a chemical barrier preventing cellular adhesion to the patch, cell migration onto the patch or cell proliferation on the patch.
  • compositions may be combined in order to achieve a desired effect (e.g., several preparations may be combined in order to achieve both a quick and a slow or prolonged release of a given factor).
  • compositions of the present invention may be formulated to contain more than one agent, to contain a variety of additional compounds, to have certain physical properties (e.g., elasticity, a particular melting point, or a specified release rate).
  • compositions and pharmaceutical compositions provided herein may be placed within containers, along with packaging material which provides instructions regarding the use of such materials. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients.
  • Patch angioplasty is mainly performed in two vascular procedures at the present time, carotid endarterectomy and profundaplasty.
  • vascular patches are also used in other vascular procedures, for example to repair iatrogenic or traumatic arterial injuries or to repair the arterial wall after resection of a saccular aneurysm.
  • the present invention could be applied to any vascular patching procedure.
  • Patch angioplasty can be performed with autologous tissue (typically a segment of the patient's veins) or synthetic material (expanded polytetrafluoroethylene or Dacron).
  • Vein patches have drawbacks such as aneurysmal degeneration and rupture (Archie et al., Surgery 1990, 107: 389-396). They require an additional incision to harvest the vein with associated morbidity. Vein harvest also increases operative time.
  • the patient's veins may not be suitable for patching. Most importantly, the vein used for the patch will not be available for coronary artery bypass grafting should the patient require arterial reconstruction at a later time. For these reasons, the use of synthetic patches has become increasingly popular.
  • Thrombus may grow large enough to cause distal ischemia. Parts of the thrombus may also become dislodged and cause embolization of distal arterioles and capillaries. In the case of carotid artery patches, thrombus occlusion and embolization lead to stroke.
  • inflammatory cells such as macrophages, lymphocytes and neutrophils adhere to the prosthetic lumen and also migrate into the peri-prosthetic space. These cells release cytokines that promote smooth muscle cell migration from the adjacent vessel on the luminal surface of the patch. The cells further proliferate on the patch and secrete extracellular matrix. Depending on the porosity of the patch material, cells may also migrate through the pores of the patch from the surrounding tissue into the lumen. In both cases, hyperplasia causes plaque formation on the luminal surface of the patch and the adjacent vessels within a few weeks. This reduces luminal area in the treated blood vessel, thus impeding blood flow to the distal tissue.
  • the present invention involves coating synthetic patches with agents preventing inflammatory reaction, thrombus formation and intimal hyperplasia in order to inhibit restenosis of the treated vessel.
  • a coated patch is trimmed and tapered to appropriate size (typically 7 cm long with a 4 mm apex and a 7 mm bulb).
  • the coated patch is placed along the edges of the arteriotomy to reconstruct the original shape of the vessel and to replace a significant portion of the endarterectomized wall of the artery.
  • the coated patch is sutured to the edges of the arteriotomy with a continuous 7-0 polypropylene suture. Blood flow is restored by releasing all clamps and the skin wound is closed.
  • the common femoral artery and the profunda femoris artery are isolated through a vertical groin incision. Once the branches distal to the end of the occlusive disease are controlled, the common femoral, superficial femoral and the PFA branches are clamped. An arteriotomy is performed, starting on the common femoral and extending down the PFA until the plaque ends. Endarterectomy of the involved common femoral and PFA is performed as needed. A coated patch is trimmed to size to achieve a smooth taper in the PFA to re-establish optimal flow characteristics in the repaired vessel. The coated patch is sutured to the edges of the arteriotomy with a continuous 7-0 polypropylene suture. Blood flow is restored by releasing all clamps and the skin wound is closed.
  • PFA profunda femoris artery
  • a sufficient quantity of polymer is weighed directly into a 20 mL glass scintillation vial, and sufficient DCM added in order to achieve a 2% w/v solution.
  • the vial is then capped and mixed by hand in order to dissolve the polymer.
  • the patch is then held in a vertical orientation with micro clamps connected to a holding apparatus 6 to 12 inches above the fume hood floor to enable horizontal spraying.
  • a suitable volume (minimum 5ml) of the 2% polymer solution is transferred to a separate 20ml glass scintillation vial.
  • An appropriate amount of paclitaxel is then added to the solution and dissolved by hand shaking.
  • the 20ml glass vial acts as a reservoir.
  • Connect the nitrogen tank to the gas inlet of the atomizer. Gradually increase the pressure until atomization and spraying begins. Note the pressure and use this pressure throughout the procedure.
  • To spray the patch use 5 second oscillating sprays with a 15 second dry time between sprays. After 5 sprays, rotate the patch 180° and spray the other side of the patch. During the dry time, finger crimp the gas line to avoid wastage of the spray. Spraying is continued until a suitable amount of polymer is deposited on the patch.
  • the amount may be based on the specific patching application in vivo. To determine the amount, weigh the patch after spraying has been completed and the patch has dried. Subtract the original weight of the patch from the finished weight. This produces the amount of polymer (plus paclitaxel) applied to the patch. Store the coated patch in a sealed container.
  • dichloromethane is added to the withdrawn supernatant and the tube is capped and shaken by hand for 1 minute to allow all the released paclitaxel to partition into the separate dichloromethane phase.
  • the tubes are then centrifuged at 500xg for 1 minute, the 10 mL of top aqueous phase are withdrawn and discarded and the dichloromethane phase is evaporated under nitrogen at 50 °C for 20 minutes.
  • One mL of a 60% acetonitrite in water (v/v) solution is added to each tube to solubilize the dried contents.
  • Two vascular clamps are placed on the artery to temporarily stop blood flow and an arteriotomy is performed between the clamps.
  • the arteriotomy is closed with a synthetic patch.
  • the animals are randomized into 4 groups of 5 pigs receiving a synthetic patch coated with (1) carrier polymer alone, (2) carrier polymer loaded with
  • paclitaxel 1% paclitaxel, (3) carrier polymer loaded with 5% paclitaxel or (4) carrier polymer loaded with 10% paclitaxel.
  • the clamps are released and the skin is closed.
  • the contralateral carotid artery is prepared in the same manner and a control uncoated patch is used to repair the arteriotomy. The animal is recovered.
  • the animals are sacrificed at 1 month and perfused with saline followed by 10% phosphate buffered formaldehyde for 30 minutes under lOOmmHg pressure.
  • the carotid arteries are removed and kept in the same fixative solution overnight.
  • the specimens are then prepared for histology.
  • Cross sections are cut and stained with H&E and Movat's stains. Histopathology of the tissue surrounding the patch is recorded.
  • Morphometric analysis is performed to measure hyperplasia on the luminal surface of the patch and in adjacent vessels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
PCT/CA2002/002017 2001-12-28 2002-12-30 Surgical patches with a biological active agent Ceased WO2003059408A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP02787305A EP1465680A2 (en) 2001-12-28 2002-12-30 Coated surgical patches
JP2003559568A JP2005514171A (ja) 2001-12-28 2002-12-30 生物学的活性薬剤を有する外科用パッチ
CA002470499A CA2470499A1 (en) 2001-12-28 2002-12-30 Surgical patches with a biological active agent
NZ533499A NZ533499A (en) 2001-12-28 2002-12-30 Surgical patches coated with biologically active agents to prevent adverse tissue reaction to the patch
BR0215397-1A BR0215397A (pt) 2001-12-28 2002-12-30 Pensos cirúrgicos revestidos
AU2002351632A AU2002351632A1 (en) 2001-12-28 2002-12-30 Surgical patches with a biological active agent
MXPA04006319A MXPA04006319A (es) 2001-12-28 2002-12-30 Parches quirurgicos recubiertos.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34401101P 2001-12-28 2001-12-28
US60/344,011 2001-12-28

Publications (2)

Publication Number Publication Date
WO2003059408A2 true WO2003059408A2 (en) 2003-07-24
WO2003059408A3 WO2003059408A3 (en) 2003-10-09

Family

ID=23348648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/002017 Ceased WO2003059408A2 (en) 2001-12-28 2002-12-30 Surgical patches with a biological active agent

Country Status (11)

Country Link
US (1) US20030216758A1 (cg-RX-API-DMAC7.html)
EP (1) EP1465680A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005514171A (cg-RX-API-DMAC7.html)
KR (1) KR20050025136A (cg-RX-API-DMAC7.html)
CN (2) CN1276780C (cg-RX-API-DMAC7.html)
AU (1) AU2002351632A1 (cg-RX-API-DMAC7.html)
BR (1) BR0215397A (cg-RX-API-DMAC7.html)
CA (1) CA2470499A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04006319A (cg-RX-API-DMAC7.html)
NZ (2) NZ533499A (cg-RX-API-DMAC7.html)
WO (1) WO2003059408A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2075014A3 (en) * 2002-05-24 2009-08-12 Angiotech International Ag Compositions and methods for coating medical implants
CN102698319A (zh) * 2012-03-02 2012-10-03 首都医科大学附属北京朝阳医院 一种抗肿瘤生物补片
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US8785156B2 (en) 2007-11-30 2014-07-22 Clarient Diagnostic Services, Inc. TLE3 as a marker for chemotherapy
WO2014186435A3 (en) * 2013-05-14 2015-02-19 University Of Georgia Research Foundation, Inc. Compositions, medical devices and grafts comprising ctp synthase 1 inhibitors and their use for reducing neointima formation

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
AU2003275263A1 (en) * 2002-09-26 2004-04-19 Angiotech International Ag Perivascular wraps
US20050158356A1 (en) * 2003-11-20 2005-07-21 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
US20050209664A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US9833618B2 (en) * 2005-02-04 2017-12-05 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20090173352A1 (en) * 2007-11-01 2009-07-09 Pavad Medical On-off implant for supporting the airway
US8690960B2 (en) * 2009-11-24 2014-04-08 Covidien Lp Reinforced tissue patch
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
CN103619177A (zh) * 2011-04-25 2014-03-05 南加州大学 通过抑制干扰素-γ和肿瘤坏死因子-α来改善组织再生的方法和组合物
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117083A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
CN109821076B (zh) * 2019-03-13 2021-05-07 陕西师范大学 一种抗凝抗感染的多功能涂层的制备方法及抗凝抗感染的多功能材料
KR20220009041A (ko) 2020-07-15 2022-01-24 문현우 당뇨병 환자를 위한 상처 치유 억제용 패치

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894000A (en) * 1971-01-27 1975-07-08 Upjohn Co Ara-cytidine derivatives and process of preparation
CH614720A5 (cg-RX-API-DMAC7.html) * 1974-10-15 1979-12-14 Asahi Chemical Ind
DE2623420C2 (de) * 1976-05-25 1978-07-06 Stiftung Deutsches Krebsforschungszentrum, 6900 Heidelberg Verfahren zur Herstellung unsymmetrisch 13-disubstituierter Nitrosoharnstoffe
US4258052A (en) * 1976-08-17 1981-03-24 Yu Ruey J Treatment of psoriasis with nicotinamide analogues
US4215062A (en) * 1978-05-22 1980-07-29 University Of Kansas Endowment Association Anthracycline synthesis
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4371540A (en) * 1979-09-14 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroimidazoles of low toxicity and high activity as radiosensitizers of hypoxic tumor cells
US4367239A (en) * 1980-09-29 1983-01-04 Kefalas A/S Nitrosourea derivatives, pharmaceutical compositions thereof and method of preparation
JPS5775993A (en) * 1980-10-30 1982-05-12 Tetsuo Suami Novel nitrosourea derivative and its preparation
US4394373A (en) * 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4462992A (en) * 1982-02-08 1984-07-31 Research Corporation Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof
US4500676A (en) * 1983-12-15 1985-02-19 Biomatrix, Inc. Hyaluronate modified polymeric articles
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5099013A (en) * 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US4841045A (en) * 1985-03-12 1989-06-20 University Of Vermont & State Agricultural College Synthesis of vinblastine and vincristine type compounds
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4841085A (en) * 1986-06-30 1989-06-20 Board Of Regents, University Of Texas System Aldophosphamides
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4913743A (en) * 1987-04-15 1990-04-03 Biomatrix, Inc. Processes for managing keratinous material using glycosaminoglycan and cationic polymer combinations
US4838888A (en) * 1987-04-17 1989-06-13 Baxter Travenol Laboratories, Inc. Calcification mitigation of implantable bioprostheses
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4908356A (en) * 1988-05-25 1990-03-13 Research Corporation Technologies, Inc. Aldophosphamide derivatives useful as antitumor agents
US5104400A (en) * 1989-05-26 1992-04-14 Impra, Inc. Blood vessel patch
US5100422A (en) * 1989-05-26 1992-03-31 Impra, Inc. Blood vessel patch
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
ATE147613T1 (de) * 1989-09-15 1997-02-15 Chiron Vision Corp Synthetisches material, das die anlagerung, das wachstum und die befestigung von epithelzellen fördert, prosthetische vorrichtung zur subepithelialen implantation sowie behandelte linse
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
JP2839164B2 (ja) * 1989-12-25 1998-12-16 帝國製薬株式会社 消炎鎮痛貼付剤
AU7998091A (en) * 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5833665A (en) * 1990-06-14 1998-11-10 Integra Lifesciences I, Ltd. Polyurethane-biopolymer composite
US5594158A (en) * 1990-06-22 1997-01-14 The Board Of Regents Of The University Of Nebraska Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin
US5143724A (en) * 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5246698A (en) * 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
TW197439B (cg-RX-API-DMAC7.html) * 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
DE69223065T2 (de) * 1991-06-14 1998-04-09 Gore & Ass Oberflächenmodifiziertes, poröses expandiertes polytetrafluoroäthylen und verfahren zur herstellung desselben
CA2071160A1 (en) * 1991-07-31 1993-02-01 Vittorio Farina Asymmetric synthesis of taxol side chain
US5283253A (en) * 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5350866A (en) * 1991-09-23 1994-09-27 Bristol-Myers Squibb Company 10-desacetoxytaxol derivatives
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5500013A (en) * 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
AU667069B2 (en) * 1991-12-06 1996-03-07 North Shore University Hospital Research Corporation Method of reducing medical device related infections
US5222964A (en) * 1992-03-03 1993-06-29 Cooper William I Intraluminal stent
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5440056A (en) * 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) * 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
WO1994005282A1 (en) * 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5411984A (en) * 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
AU5605994A (en) * 1992-11-12 1994-06-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for determining the presence of functional p53 in mammalian cells
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5279949A (en) * 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5399352A (en) * 1993-04-14 1995-03-21 Emory University Device for local drug delivery and methods for using the same
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
CA2167715C (en) * 1993-07-20 1998-10-06 Akiyoshi Kawai Heteroaryl cycloalkenyl hydroxyureas
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5653730A (en) * 1993-09-28 1997-08-05 Hemodynamics, Inc. Surface opening adhesive sealer
US5395850A (en) * 1994-03-10 1995-03-07 Bristol-Myers Squibb Company 6,7-epoxy paclitaxels
FI951367A7 (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
DE69419265T2 (de) * 1994-07-27 2000-01-05 W.L. Gore & Associates, Inc. Höchfeste poröse folie aus ptfe
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US6025480A (en) * 1995-04-03 2000-02-15 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecules encoding P57KIP2
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
EP0874643B1 (en) * 1996-02-15 2001-11-21 J. Paul Santerre Bioresponsive pharmacologically-active polymers and articles made therefrom
US5744349A (en) * 1996-03-05 1998-04-28 Washington University DNA sequences encoding human Myt1 kinase
US5942555A (en) * 1996-03-21 1999-08-24 Surmodics, Inc. Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom
US5800412A (en) * 1996-10-10 1998-09-01 Sts Biopolymers, Inc. Hydrophilic coatings with hydrating agents
US6106473A (en) * 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
US5879697A (en) * 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6110483A (en) * 1997-06-23 2000-08-29 Sts Biopolymers, Inc. Adherent, flexible hydrogel and medicated coatings
US6121027A (en) * 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
GB9719426D0 (en) * 1997-09-13 1997-11-12 Johnson Matthey Plc Novel process
US6197036B1 (en) * 1997-10-01 2001-03-06 Scimed Life Systems, Inc. Pelvic floor reconstruction
US6100032A (en) * 1998-03-13 2000-08-08 Johns Hopkins University Human Smad3 and Smad4 are sequence-specific transcription activators
PT1019111E (pt) * 1998-04-27 2002-10-31 Surmodics Inc Revestimento que liberta um agente bioactivo
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6528107B2 (en) * 1999-01-19 2003-03-04 Sulzer Carbomedics Inc. Method for producing antimicrobial antithrombogenic medical devices
US6224579B1 (en) * 1999-03-31 2001-05-01 The Trustees Of Columbia University In The City Of New York Triclosan and silver compound containing medical devices
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
EP1247537A1 (en) * 2001-04-04 2002-10-09 Isotis B.V. Coating for medical devices

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2075014A3 (en) * 2002-05-24 2009-08-12 Angiotech International Ag Compositions and methods for coating medical implants
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US8372420B2 (en) 2002-05-24 2013-02-12 Angiotech International Ag Compositions and methods for coating medical implants
US8785156B2 (en) 2007-11-30 2014-07-22 Clarient Diagnostic Services, Inc. TLE3 as a marker for chemotherapy
US9005900B2 (en) 2007-11-30 2015-04-14 Clarient Diagnostic Services, Inc. TLE3 as a marker for chemotherapy
CN102698319A (zh) * 2012-03-02 2012-10-03 首都医科大学附属北京朝阳医院 一种抗肿瘤生物补片
WO2014186435A3 (en) * 2013-05-14 2015-02-19 University Of Georgia Research Foundation, Inc. Compositions, medical devices and grafts comprising ctp synthase 1 inhibitors and their use for reducing neointima formation
US10328182B2 (en) 2013-05-14 2019-06-25 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
US11246965B2 (en) 2013-05-14 2022-02-15 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation

Also Published As

Publication number Publication date
WO2003059408A3 (en) 2003-10-09
CA2470499A1 (en) 2003-07-24
EP1465680A2 (en) 2004-10-13
JP2005514171A (ja) 2005-05-19
MXPA04006319A (es) 2005-03-31
KR20050025136A (ko) 2005-03-11
NZ546343A (en) 2008-03-28
CN1911453A (zh) 2007-02-14
CN1610565A (zh) 2005-04-27
US20030216758A1 (en) 2003-11-20
NZ533499A (en) 2006-12-22
BR0215397A (pt) 2004-12-07
CN1276780C (zh) 2006-09-27
AU2002351632A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
US20030216758A1 (en) Coated surgical patches
US20040260318A1 (en) Anastomotic connector devices
EP1594459B1 (en) Drug delivery from rapid gelling polymer composition
US20040219214A1 (en) Tissue reactive compounds and compositions and uses thereof
US20020055666A1 (en) Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US20030144570A1 (en) Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
CA2536181A1 (en) Polymer compositions and methods for their use
EP2075014A2 (en) Compositions and methods for coating medical implants
CA2536042A1 (en) Medical implants and anti-scarring agents
WO2007089878A2 (en) Sutures and anti-scarring agents
EP2944330A1 (en) Artificial blood vessel using decellularized blood vessel sheet
HK1074806A (en) Surgical patches with a biological active agent
HK1083067B (en) Drug delivery from rapid gelling polymer composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 00794/KOLNP/2004

Country of ref document: IN

Ref document number: 794/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 533499

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2470499

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/006319

Country of ref document: MX

Ref document number: 2003559568

Country of ref document: JP

Ref document number: 1020047010174

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028263707

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002351632

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002787305

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002787305

Country of ref document: EP